An unnamed pharma company asked regulators to change how the FDA publicly discloses complete response letters. The citizen petition targets the FDA’s July 2025 policy to release CRLs, arguing the current process risks disclosure of competitively sensitive and proprietary information and asking for a clearer contestation mechanism before publication. The petition requests that FDA inform manufacturers in advance of intended CRL disclosure, provide a short window to respond, and explain the rationale in writing if the agency proceeds despite objections. The FDA’s CRL disclosure “radical transparency” approach has drawn investor praise for improving accountability. The move highlights ongoing tension between regulator transparency and sponsor IP confidentiality, with potential implications for how future review outcomes are communicated to the market. The FDA is required to respond to citizen petitions within 180 days of receipt.